Healthcare Global Enterprises Limited — PPTs, 06-02-2026: Investor Presentation

Here's a concise, retail-friendly summary:

**1. Business Performance:**

HCG posted robust Q3FY26 revenue, up 13% YoY to ₹633.1 Cr. Excl. fertility, revenue grew via 8% higher volumes & 5% ARPP. West cluster revenue rose 17% YoY, with international business surging 42%. 9MFY26 overall revenue was up 16% to ₹1,893.1 Cr.

**2. Growth Drivers or Strategy:**

HCG focuses on network optimization via talent and international scaling. Strategies include brownfield expansion, new market entry, and efficiency gains through cost control and leveraging advanced digital/medical technology.

**3. Recent Developments:**

HCG augmented senior leadership across marketing, sales, and tech. The new North Bangalore Greenfield Hospital, featuring advanced MR-LINAC technology, is set to open by Q4FY26, promising a new benchmark in cancer care.

**4. Key Financial Metrics:**

Q3FY26 Adj. EBITDA grew 20% YoY to ₹110.8 Cr, margins improving to 17.5%. 9MFY26 Adj. EBITDA was up 20% to ₹345.8 Cr, reaching 18.3% margins. 9MFY26 ROCE (pre-tax) stood at 13.3%.

**5. Management Commentary / Outlook:**

Management aims to expand HCG's oncology platform, strengthen clinical excellence, and improve patient outcomes. The new North Bangalore facility underscores their dedication to advanced technology and market leadership.